Logout
 CME Information
 Editorial Board
 Lessons by Volume
   Volume 22
   Volume 21
   Volume 20
   Volume 19
   Volume 18
   Volume 17
   Volume 16
   Volume 15
 
 

Mesothelioma Update

By Mark Block, MD; and Alice M. Boylan, MD

Print This | TOC | Previous | Next

References

  1. Britton M. The epidemiology of mesothelioma. Semin Oncol 2002; 29:18–25
  2. Strickler HD. A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol Biomarkers Prev 2001; 10:523–532
  3. Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998; 279:292–295
  4. Roggli V, McGavran M, Subach J, et al. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. Cancer 1982; 50:2423–2432
  5. Huncharek M. Changing risk groups for malignant mesothelioma. Cancer 1992; 69:2704–2711
  6. Ruffie P, Minkin F, Cormier Y, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7:1157–1168
  7. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 patients. Cancer 1993; 72:389–393
  8. Patz E, Shaffer K, Piwnica-Worms D, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 159:961–966
  9. Bernard F, Sterman D, Smith R, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 111:106–109
  10. Adams RF, Gray W, Davies RJ, et al. Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest 2001; 120:1798–1802
  11. McCaughey W, Colby T, Battifora H, et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. 1991; 4:342–354
  12. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 1995; 108:1122–1128
  13. Metintas M, Metintas S, Ucgun I et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 2001; 95:829–835
  14. Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann thorac Surg 2000; 69:369-375
  15. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655-1658
  16. Sugarbaker D, Flores R, Jaklitsch M, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117:54–56
  17. Pass H, Kranda K, Temeck B, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 1997; 4:215–222
  18. Rusch V, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996; 111:815–826
  19. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999; 68:1799–1804
  20. Pass H, Temeck B, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997; 4:628–633
  21. Ryan C, Herndon J, Vogelzang N. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113:66S–73S
  22. Byrne M, Davidson J, Musk A, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17:25–30
  23. Nakano T, Chahiniian A, Shinjo M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma. Cancer 1999; 85:2375–2384
  24. Fizazi K, John WJ, Vogelzang NJ. The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin Oncol 2002; 29:77–81
  25. Goey S, Eggermont A, Punt C, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995; 72:1283–1288
  26. Boutin C, Nussbaum E, Monnet I. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74:2460–2467
  27. Sterman D, Treat J, Litzky L, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083–1092
  28. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274–281

Copyright ©2003 American College of Chest Physicians

Print This | TOC | Previous | Next

 
 

3300 Dundee Road • Northbrook, Illinois 60062-2348 • (847) 498-1400 • (800) 343-2227
Copyright ©1999-2008 American College of Chest Physicians. All Rights Reserved.
ACCP Privacy Policy | ACCP Web Site Terms of Use